GR3004912T3 - - Google Patents

Info

Publication number
GR3004912T3
GR3004912T3 GR920401262T GR920401262T GR3004912T3 GR 3004912 T3 GR3004912 T3 GR 3004912T3 GR 920401262 T GR920401262 T GR 920401262T GR 920401262 T GR920401262 T GR 920401262T GR 3004912 T3 GR3004912 T3 GR 3004912T3
Authority
GR
Greece
Application number
GR920401262T
Other languages
Greek (el)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK503386A external-priority patent/DK503386D0/da
Priority claimed from DK356987A external-priority patent/DK356987D0/da
Application filed filed Critical
Publication of GR3004912T3 publication Critical patent/GR3004912T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
GR920401262T 1986-10-20 1992-06-11 GR3004912T3 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK503386A DK503386D0 (da) 1986-10-20 1986-10-20 Peptidpraeparater
DK356987A DK356987D0 (cg-RX-API-DMAC7.html) 1987-07-10 1987-07-10

Publications (1)

Publication Number Publication Date
GR3004912T3 true GR3004912T3 (cg-RX-API-DMAC7.html) 1993-04-28

Family

ID=26067111

Family Applications (1)

Application Number Title Priority Date Filing Date
GR920401262T GR3004912T3 (cg-RX-API-DMAC7.html) 1986-10-20 1992-06-11

Country Status (18)

Country Link
US (1) US5070186A (cg-RX-API-DMAC7.html)
EP (1) EP0265213B1 (cg-RX-API-DMAC7.html)
KR (1) KR880004819A (cg-RX-API-DMAC7.html)
CN (1) CN87107049A (cg-RX-API-DMAC7.html)
AU (1) AU616381B2 (cg-RX-API-DMAC7.html)
CA (1) CA1316819C (cg-RX-API-DMAC7.html)
DE (1) DE3778287D1 (cg-RX-API-DMAC7.html)
ES (1) ES2033871T3 (cg-RX-API-DMAC7.html)
FI (1) FI86254C (cg-RX-API-DMAC7.html)
GR (1) GR3004912T3 (cg-RX-API-DMAC7.html)
HU (1) HU201475B (cg-RX-API-DMAC7.html)
IE (1) IE60264B1 (cg-RX-API-DMAC7.html)
IL (1) IL84203A (cg-RX-API-DMAC7.html)
NO (1) NO170754C (cg-RX-API-DMAC7.html)
NZ (1) NZ222214A (cg-RX-API-DMAC7.html)
PH (1) PH23446A (cg-RX-API-DMAC7.html)
PT (1) PT85949B (cg-RX-API-DMAC7.html)
YU (1) YU46665B (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534488A (en) * 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
AR002976A1 (es) * 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
EP1044016B1 (en) * 1998-01-09 2005-03-16 Novo Nordisk A/S Stabilised insulin compositions
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
PL366787A1 (en) * 2001-08-27 2005-02-07 Novo Nordisk A/S A cartridge and a medical delivery system accommodating such a cartridge
CA2512052C (en) * 2002-12-31 2016-06-21 Altus Pharmaceuticals Inc. Human growth hormone crystals and methods for preparing them
NZ554885A (en) * 2002-12-31 2009-07-31 Altus Pharmaceuticals Inc Complexes of hgh crystals and protamine polymers
US20090023629A1 (en) * 2005-12-23 2009-01-22 Altus Pharmaceuticals Inc. Compositions comprising polycation-complexed protein crystals and methods of treatment using them
WO2008015099A2 (en) 2006-07-31 2008-02-07 Novo Nordisk A/S Pegylated, extended insulins
KR101729986B1 (ko) 2006-09-22 2017-04-25 노보 노르디스크 에이/에스 프로테아제 내성 인슐린 유사체
WO2008132224A2 (en) 2007-04-30 2008-11-06 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
US20100120660A1 (en) * 2007-04-30 2010-05-13 Per Balschmidt Highly concentrated insulin solutions and compositions
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
DK2910570T3 (en) 2008-03-18 2017-01-30 Novo Nordisk As Protease-stabilized acylated insulin analogues.
PL3228320T3 (pl) 2008-10-17 2020-06-01 Sanofi-Aventis Deutschland Gmbh Kombinacja insuliny i agonisty GLP-1
SI2498801T1 (en) 2009-11-13 2018-06-29 Sanofi-Aventis Deutschland Gmbh A pharmaceutical composition containing desPro36Exendin-4 (1-39) -Lys6-NH2 and methionine
CA3011480C (en) 2009-11-13 2021-11-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
CN101912600B (zh) * 2010-01-11 2014-01-29 杨国汉 改善胰岛素在溶液中稳定性的方法
US8637458B2 (en) * 2010-05-12 2014-01-28 Biodel Inc. Insulin with a stable basal release profile
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
EP2611458B1 (en) 2010-08-30 2016-09-21 Sanofi-Aventis Deutschland GmbH Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
EP2750699B1 (en) 2011-08-29 2015-07-22 Sanofi-Aventis Deutschland GmbH Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9481721B2 (en) 2012-04-11 2016-11-01 Novo Nordisk A/S Insulin formulations
US9381247B2 (en) * 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
US9399065B2 (en) 2012-04-16 2016-07-26 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and injection site pain of insulin
EP4613284A3 (en) 2013-04-03 2025-11-19 Sanofi Treatment of diabetes mellitus by long-acting formulations of insulins
MX366636B (es) 2013-10-07 2019-07-17 Novo Nordisk As Nuevo derivado de un análogo de insulina.
PE20171622A1 (es) 2014-12-12 2017-11-02 Sanofi Aventis Deutschland Formulacion de relacion fija de insulina glargina/lixisenatida
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
TWI700091B (zh) 2016-12-16 2020-08-01 丹麥商諾佛 儂迪克股份有限公司 含胰島素醫藥組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2076082A (en) * 1935-04-08 1937-04-06 Nordisk Insulinlab Therapeutic product and process
US2179384A (en) * 1937-04-05 1939-11-07 Univ Alberta Therapeutic composition and process of making it
US2190134A (en) * 1939-06-09 1940-02-13 Norton Co Grinding machine
US2538018A (en) * 1944-04-04 1951-01-16 Nordisk Insulinlab Crystalline product of insulin and alkaline protein and process of making it
US2474729A (en) * 1945-01-03 1949-06-28 Rhone Poulenc Sa Insulin preparations
US2801953A (en) * 1952-02-28 1957-08-06 Hoechst Ag Process of preparing crystallized insulin preparations
US3102077A (en) * 1953-08-19 1963-08-27 Christensen Henry Marinus Preparation of insulin containing 2.75 to 8 percent zinc content
DK98342C (da) * 1959-06-16 1964-03-31 Henry Marinus Dr Christensen Fremgangsmåde til fremstilling af et insulinpræparat til peroral applikation.
US3868358A (en) * 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
GB1426061A (en) * 1972-12-28 1976-02-25 Ici Ltd Polypeptides
US3856771A (en) * 1973-07-16 1974-12-24 Lilly Co Eli Process for manufacturing alkali metal or ammonium insulin
US4196196A (en) * 1978-06-19 1980-04-01 Tiholiz Ivan C Divalen/monovalent bipolar cation therapy for enhancement of tissue perfusion and reperfusion in disease states
AU550068B2 (en) * 1981-03-10 1986-02-27 Novo Nordisk A/S Zinc insulin stabilized with calcium or magnesium salts
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
US4764592A (en) * 1987-04-23 1988-08-16 Eli Lilly And Company Crystalline human proinsulin and process for its production

Also Published As

Publication number Publication date
EP0265213B1 (en) 1992-04-15
DE3778287D1 (de) 1992-05-21
NO874347D0 (no) 1987-10-19
YU46665B (sh) 1994-01-20
EP0265213A2 (en) 1988-04-27
CN87107049A (zh) 1988-07-06
YU191887A (en) 1989-04-30
AU7990787A (en) 1988-04-21
PT85949B (pt) 1990-07-31
ES2033871T3 (es) 1993-04-01
FI874596L (fi) 1988-04-21
IE60264B1 (en) 1994-06-29
PH23446A (en) 1989-08-07
NZ222214A (en) 1989-11-28
NO170754C (no) 1992-12-02
KR880004819A (ko) 1988-06-27
HUT46232A (en) 1988-10-28
EP0265213A3 (en) 1988-11-09
IL84203A (en) 1993-04-04
FI86254B (fi) 1992-04-30
NO170754B (no) 1992-08-24
FI86254C (fi) 1992-08-10
CA1316819C (en) 1993-04-27
FI874596A0 (fi) 1987-10-19
IE872799L (en) 1988-04-20
US5070186A (en) 1991-12-03
AU616381B2 (en) 1991-10-31
HU201475B (en) 1990-11-28
NO874347L (no) 1988-04-21
PT85949A (en) 1987-11-01

Similar Documents

Publication Publication Date Title
IN167102B (cg-RX-API-DMAC7.html)
AU7131891A (cg-RX-API-DMAC7.html)
IN170407B (cg-RX-API-DMAC7.html)
GR3004912T3 (cg-RX-API-DMAC7.html)
GR3006472T3 (cg-RX-API-DMAC7.html)
FR2602942B1 (cg-RX-API-DMAC7.html)
IN170454B (cg-RX-API-DMAC7.html)
GR3006632T3 (cg-RX-API-DMAC7.html)
IN168007B (cg-RX-API-DMAC7.html)
AU6562586A (cg-RX-API-DMAC7.html)
AU7131791A (cg-RX-API-DMAC7.html)
AU5878886A (cg-RX-API-DMAC7.html)
AU4910985A (cg-RX-API-DMAC7.html)
BE905088A (cg-RX-API-DMAC7.html)
AU6161186A (cg-RX-API-DMAC7.html)
AU6098786A (cg-RX-API-DMAC7.html)
AU6053586A (cg-RX-API-DMAC7.html)
AU6019186A (cg-RX-API-DMAC7.html)
AU5130385A (cg-RX-API-DMAC7.html)
AU5597686A (cg-RX-API-DMAC7.html)
AU6014586A (cg-RX-API-DMAC7.html)
AU6011386A (cg-RX-API-DMAC7.html)
AU5982886A (cg-RX-API-DMAC7.html)
AU5644686A (cg-RX-API-DMAC7.html)
AU5940986A (cg-RX-API-DMAC7.html)